The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
 
Marie N. Becker
No Relationships to Disclose
 
Jame Abraham
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst); Seagen (Inst)
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
Laura Spring
Consulting or Advisory Role - AstraZeneca; Daiichi Pharma; G1 Therapeutics; Novartis; Puma Biotechnology
Research Funding - Genentech/Roche; Gilead Sciences; Lilly; Merck (Inst); Philips Healthcare (Inst)
 
Tiffany A. Traina
Consulting or Advisory Role - Agendia; AstraZeneca; bioTheranostics; Blueprint Medicines; Daiichi Sankyo; Ellipses Pharma; Fuji Pharma; G1 Therapeutics; GE Healthcare; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Infinity Pharmaceuticals; ITeos Therapeutics; Merck; Novartis; Pfizer; SeaGen; Tersera
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Carrick Pharm (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Timothy A. Quill
No Relationships to Disclose
 
Denise A. Yardley
Consulting or Advisory Role - AstraZeneca (Inst); Athenex (Inst); Biotheranostics (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Biomarin (Inst); Biothera (Inst); Clovis Oncology (Inst); Dana Farber Cancer Hospital (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); NSABP Foundation (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Polyphor (Inst)